The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for ...

It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

The government has received a $600 million (about Shs2.205 trillion) grant from the Global Fund to treat HIV/Aids, ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to the chosen companies until the selected generic manufacturers are able to ...